HB Wealth Management LLC Raises Stock Position in Bristol Myers Squibb Company $BMY

HB Wealth Management LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 26.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 109,993 shares of the biopharmaceutical company’s stock after purchasing an additional 22,867 shares during the period. HB Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $6,671,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Counterpoint Mutual Funds LLC increased its position in Bristol Myers Squibb by 1,173.8% during the first quarter. Counterpoint Mutual Funds LLC now owns 69,463 shares of the biopharmaceutical company’s stock valued at $4,213,000 after acquiring an additional 64,010 shares during the last quarter. Plimoth Trust Co. LLC boosted its position in Bristol Myers Squibb by 2.6% in the first quarter. Plimoth Trust Co. LLC now owns 26,002 shares of the biopharmaceutical company’s stock worth $1,577,000 after purchasing an additional 668 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV grew its stake in shares of Bristol Myers Squibb by 65.0% during the 1st quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 16,884 shares of the biopharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 6,650 shares during the period. IRON Financial LLC bought a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at about $224,000. Finally, Leelyn Smith LLC increased its position in shares of Bristol Myers Squibb by 0.8% during the 1st quarter. Leelyn Smith LLC now owns 58,091 shares of the biopharmaceutical company’s stock valued at $3,523,000 after purchasing an additional 457 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

BMY has been the topic of a number of research reports. Cantor Fitzgerald raised their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $58.05 on Friday. The stock has a market cap of $118.54 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a fifty day moving average price of $56.90 and a 200-day moving average price of $57.49. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.